BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

Bristol-Myers Squibb income statement 1987–2026

50.03B USD over the last twelve months, and 48.20B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
50.03B48.20B48.30B45.01B46.16B46.39B42.52B26.15B22.56B20.78B19.43B
Revenue growth
+4.16%-0.22%+7.32%-2.50%-0.49%+9.10%+62.62%+15.89%+8.59%+6.94%+17.31%
Cost of revenue
15.39B13.94B13.97B10.69B10.14B9.94B11.77B8.08B6.47B6.01B4.97B
Gross profit
34.64B34.26B34.33B34.31B36.02B36.45B30.75B18.07B16.09B14.76B14.46B
Gross margin
69.24%71.08%71.08%76.24%78.04%78.57%72.31%69.10%71.34%71.05%74.42%
Research and development
10.56B9.95B11.16B9.30B9.51B10.20B11.14B6.15B6.33B6.47B5.01B
Selling, general and administrative
7.32B7.27B8.41B7.77B7.81B7.69B7.66B4.87B4.55B4.75B4.98B
Operating expenses
21.60B20.54B28.45B26.12B26.92B27.91B28.57B12.15B10.98B11.32B9.99B
13.05B13.72B5.89B8.20B9.10B8.54B2.18B5.91B5.11B3.45B4.47B
Operating income growth
+14.24%+133.12%-28.16%-9.98%+6.64%+292.15%-63.18%+15.62%+48.40%-22.86%+158.21%
Operating margin
26.07%28.48%12.19%18.21%19.72%18.40%5.12%22.62%22.67%16.59%22.99%
Interest income
———————————
Interest expense
1.65B1.89B1.95B1.17B1.23B1.33B1.42B656.00M183.00M196.00M167.00M
Other non-operating income
-1.71B-4.40B-14.27B245.00M-1.39B-439.00M-9.05B-938.00M854.00M1.69B1.45B
Pretax income
11.33B9.33B-8.38B8.44B7.71B8.10B-6.87B4.98B5.97B5.13B5.92B
Income tax
2.09B2.27B554.00M400.00M1.37B1.08B2.12B1.52B1.02B4.16B1.41B
Effective tax rate
18.43%24.36%—4.74%17.74%13.39%—30.45%17.11%81.00%23.80%
9.24B7.05B-8.95B8.03B6.33B6.99B-9.02B3.44B4.92B1.01B4.46B
Net income growth
+53.06%—-211.50%+26.84%-9.54%—-362.14%-30.10%+388.58%-77.41%+184.79%
Net margin
18.47%14.64%-18.53%17.83%13.71%15.08%-21.20%13.15%21.81%4.85%22.94%
Basic shares
2.04B2.04B2.03B2.07B2.13B2.22B2.26B1.71B1.63B1.65B1.67B
Diluted shares
2.05B2.04B2.03B2.08B2.15B2.25B2.26B1.71B1.64B1.65B1.68B
Change in diluted shares
+0.44%+0.69%-2.45%-3.17%-4.41%-0.58%+31.89%+4.58%-0.91%-1.67%+0.06%
EPS (basic)
4.523.46-4.413.882.973.15-3.982.023.030.612.67
EPS (diluted)
4.513.45-4.413.862.953.12-3.982.013.030.612.65
EPS growth
+52.61%—-214.25%+30.85%-5.45%—-298.01%-33.66%+396.72%-76.98%+173.20%
Dividends per share
2.512.482.402.282.161.472.291.641.601.561.14
Dividend growth
+2.03%+3.33%+5.26%+5.56%+46.94%-35.81%+39.63%+2.50%+2.56%+36.84%-23.49%
EBITDA
15.15B15.23B3.17B19.37B19.22B20.12B4.93B7.38B6.79B6.12B6.46B
EBITDA margin
30.28%31.60%6.56%43.03%41.64%43.37%11.59%28.22%30.09%29.44%33.27%
EBIT
12.99B11.22B-6.43B9.61B8.95B9.43B-5.45B5.63B6.15B5.33B6.08B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Bristol-Myers Squibb's income statement

Source: Financial Modeling PrepVerified against SEC filings